Ghent University Academic Bibliography

Advanced

Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study

Kevin Hollevoet UGent, Joris Van Cleemput, Joel Thimpont, Paul De Vuyst, Lionel Bosquee, Kristiaan Nackaerts, Paul Germonpre, Stijn Vansteelandt UGent, Yoshiro Kishi and Joris Delanghe UGent, et al. (2011) JOURNAL OF THORACIC ONCOLOGY. 6(5). p.889-895
abstract
Introduction: Soluble mesothelin (SM) and megakaryocyte potentiating factor (MPF) are serum biomarkers of mesothelioma. This study aims to examine the longitudinal behavior of SM and MPF in controls to gain insight in the optimal use of these biomarkers in screening. Methods: Asbestos-exposed individuals, with no malignant disease at inclusion, were surveilled for 2 years with annual measurements of SM and MPF. Fixed thresholds were set at 2.10 nmol/L for SM and 13.10 ng/ml for MPF. Longitudinal biomarker analysis, using a random intercept model, estimated the association with age and glomerular filtration rate (GFR), and the intraclass correlation. The latter represents the proportion of total biomarker variance accounted for by the between-individual variance. Results: A total of 215 participants were included, of whom 179 and 137 provided a second sample and third sample, respectively. Two participants with normal SM and MPF levels presented afterward with mesothelioma and lung cancer, respectively. Participants with elevated biomarker levels were typically older and had a lower GFR. During follow-up, biomarker levels significantly increased. Longitudinal analysis indicated that this was in part due to aging, while changes in GFR had a less pronounced effect on serial biomarker measurements. SM and MPF had a high intraclass correlation of 0.81 and 0.78, respectively, which implies that a single biomarker measurement and fixed threshold are suboptimal in screening. Conclusions: The longitudinal behavior of SM and MPF in controls indicates that a biomarker-based screening approach can benefit from the incorporation of serial measurements and individual-specific screening rules, adjusted for age and GFR. Large-scale validation remains nevertheless mandatory to elucidate whether such an approach can improve the early detection of mesothelioma.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
Screening, Mesothelioma, Megakaryocyte potentiating factor, MALIGNANT PLEURAL MESOTHELIOMA, MEGAKARYOCYTE POTENTIATING FACTOR, GLOMERULAR-FILTRATION-RATE, SOLUBLE MESOTHELIN, OVARIAN-CANCER, Soluble mesothelin, TUMOR-MARKER, Asbestos, PROTEIN
journal title
JOURNAL OF THORACIC ONCOLOGY
J. Thorac. Oncol.
volume
6
issue
5
pages
889 - 895
Web of Science type
Article
Web of Science id
000289554100008
JCR category
RESPIRATORY SYSTEM
JCR impact factor
3.661 (2011)
JCR rank
9/48 (2011)
JCR quartile
1 (2011)
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31820db377
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1954944
handle
http://hdl.handle.net/1854/LU-1954944
date created
2011-11-28 15:11:27
date last changed
2012-02-28 11:01:53
@article{1954944,
  abstract     = {Introduction: Soluble mesothelin (SM) and megakaryocyte potentiating factor (MPF) are serum biomarkers of mesothelioma. This study aims to examine the longitudinal behavior of SM and MPF in controls to gain insight in the optimal use of these biomarkers in screening. Methods: Asbestos-exposed individuals, with no malignant disease at inclusion, were surveilled for 2 years with annual measurements of SM and MPF. Fixed thresholds were set at 2.10 nmol/L for SM and 13.10 ng/ml for MPF. Longitudinal biomarker analysis, using a random intercept model, estimated the association with age and glomerular filtration rate (GFR), and the intraclass correlation. The latter represents the proportion of total biomarker variance accounted for by the between-individual variance. Results: A total of 215 participants were included, of whom 179 and 137 provided a second sample and third sample, respectively. Two participants with normal SM and MPF levels presented afterward with mesothelioma and lung cancer, respectively. Participants with elevated biomarker levels were typically older and had a lower GFR. During follow-up, biomarker levels significantly increased. Longitudinal analysis indicated that this was in part due to aging, while changes in GFR had a less pronounced effect on serial biomarker measurements. SM and MPF had a high intraclass correlation of 0.81 and 0.78, respectively, which implies that a single biomarker measurement and fixed threshold are suboptimal in screening. Conclusions: The longitudinal behavior of SM and MPF in controls indicates that a biomarker-based screening approach can benefit from the incorporation of serial measurements and individual-specific screening rules, adjusted for age and GFR. Large-scale validation remains nevertheless mandatory to elucidate whether such an approach can improve the early detection of mesothelioma.},
  author       = {Hollevoet, Kevin and Van Cleemput, Joris and Thimpont, Joel and De Vuyst, Paul and Bosquee, Lionel and Nackaerts, Kristiaan and Germonpre, Paul and Vansteelandt, Stijn and Kishi, Yoshiro and Delanghe, Joris and Van Meerbeeck, Jan},
  issn         = {1556-0864},
  journal      = {JOURNAL OF THORACIC ONCOLOGY},
  keyword      = {Screening,Mesothelioma,Megakaryocyte potentiating factor,MALIGNANT PLEURAL MESOTHELIOMA,MEGAKARYOCYTE POTENTIATING FACTOR,GLOMERULAR-FILTRATION-RATE,SOLUBLE MESOTHELIN,OVARIAN-CANCER,Soluble mesothelin,TUMOR-MARKER,Asbestos,PROTEIN},
  language     = {eng},
  number       = {5},
  pages        = {889--895},
  title        = {Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study},
  url          = {http://dx.doi.org/10.1097/JTO.0b013e31820db377},
  volume       = {6},
  year         = {2011},
}

Chicago
Hollevoet, Kevin, Joris Van Cleemput, Joel Thimpont, Paul De Vuyst, Lionel Bosquee, Kristiaan Nackaerts, Paul Germonpre, et al. 2011. “Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-exposed Individuals: a Prospective Longitudinal Cohort Study.” Journal of Thoracic Oncology 6 (5): 889–895.
APA
Hollevoet, K., Van Cleemput, J., Thimpont, J., De Vuyst, P., Bosquee, L., Nackaerts, K., Germonpre, P., et al. (2011). Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. JOURNAL OF THORACIC ONCOLOGY, 6(5), 889–895.
Vancouver
1.
Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K, et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. JOURNAL OF THORACIC ONCOLOGY. 2011;6(5):889–95.
MLA
Hollevoet, Kevin, Joris Van Cleemput, Joel Thimpont, et al. “Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-exposed Individuals: a Prospective Longitudinal Cohort Study.” JOURNAL OF THORACIC ONCOLOGY 6.5 (2011): 889–895. Print.